Deal watch: AbbVie invests in pioneering celiac disease therapy

Crunkhorn, Sarah
July 2013
Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p497
Academic Journal
The article reports on the partnership formed between AbbVie and Alvine Pharmaceuticals to develop ALV003, a novel oral treatment being developed for patients with celiac disease. Information of the terms of the partnership agreement is provided, as well as the pathogenesis of celiac disease. The components of ALV003 include a modified recombinant version of a Hordeum vulgare cystein endoprotease and a modified recombinant version of a Sphingomonas capsulata prolyl endopeptidase.


Related Articles

  • AbbVie and Alvine Will Collaborate on Celiac Disease Therapy.  // Pharmaceutical Technology;Jun2013, Vol. 37 Issue 6, p68 

    The article reports on the collaboration of the pharmaceutical companies AbbVie Inc. and Alvine Pharmaceuticals Inc. to develop an oral treatment for patients with celiac disease.

  • Alvine and Dandy: Option Deal Brings $70M AbbVie Up Front. Osborne, Randy // BioWorld Today;5/15/2013, Vol. 24 Issue 93, p1 

    The article reports that the 70 million U.S. dollar up front from AbbVine Inc. buys an option for the firm to acquire ALV003, a drug candidate for celiac disease developed by Alvine Pharmaceuticals Inc. or the company itself. It reports that the Phase IIb trials for ALV003, a two-enzyme combo...

  • Alvine Pharmaceuticals Announces Issuance of US Patents for Enzyme Use in Celiac Disease.  // Biomedical Market Newsletter;5/17/2011, p349 

    The article reports on the announcement by Alvine Pharmaceuticals Inc. for the U.S. Patent and Trademark Office's issuance of four patents for the use of enzyme in celiac disease diagnosis. It states that patents cover the methods for gluten degradation, identification of proteases for gluten...

  • Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutations. A. Lupi; R. Tenni; A. Rossi; G. Cetta; A. Forlino // Amino Acids;Nov2008, Vol. 35 Issue 4, p739 

    Abstract  Here we summarized what is known at the present about function, structure and effect of mutations in the human prolidase. Among the peptidases, prolidase is the only metalloenzyme that cleaves the iminodipeptides containing a proline or hydroxyproline residue at the C-terminal...

  • Editorial [Hot Topic: Proteases as Targets in Medicinal Chemistry (Guest Editor: Dr. Tim F. Tam)]. Tam, Tim F. // Current Topics in Medicinal Chemistry;Feb2006, Vol. 6 Issue 4, p287 

    Protease inhibitors are used to treat and manage a variety of diseases, and have made its mark in drug development. Angiotensin converting enzyme (ACE) inhibitors such as captopril, enalapril, lisinopril, fosinopril, quinapril and ramipril are used to control blood pressure in hypertensive...

  • Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. Altmeppen, Hermann C.; Prox, Johannes; Puig, Berta; Kluth, Mark A; Bernreuther, Christian; Thurm, Dana; Jorissen, Ellen; Petrowitz, Bettina; Bartsch, Udo; De Strooper, Bart; Saftig, Paul; Glatzel, Markus // Molecular Neurodegeneration;2011, Vol. 6 Issue 1, p36 

    Background: The cellular prion protein (PrPC) fulfils several yet not completely understood physiological functions. Apart from these functions, it has the ability to misfold into a pathogenic scrapie form (PrPSc) leading to fatal transmissible spongiform encephalopathies. Proteolytic processing...

  • Role of AIF in cardiac apoptosis in hypertrophic cardiomyocytes from Dahl salt-sensitive rats. Choudhury, Sangita; Bae, Soochan; Kumar, Sheetal R.; Ke, Qingen; Yalamarti, Bhargavi; Choi, Jun H.; Kirshenbaum, Lorrie A.; Kang, Peter M. // Cardiovascular Research;Jan2010, Vol. 85 Issue 1, p28 

    Aims: The caspases are thought to be central mediators of the apoptotic program, but recent data indicate that apoptosis may also be mediated by caspase-independent mechanisms such as apoptosis-inducing factor (AIF). The role of AIF-induced apoptosis in heart, however, is currently not well...

  • Latent transforming growth factor-β: Structural features and mechanisms of activation. Munger, John S.; Harpel, John G.; Gleizes, Pierre-Emmanuel; Mazzieri, Roberta; Nunes, Irene; Rifkin, Daniel B. // Kidney International;May1997, Vol. 51 Issue 5, p1376 

    ransforming growth factor-β are cytokines with a wide range of biological effects. They play a pathologic role in inflammatory and fibrosing diseases such as nephrosclerosis. TGF-βs are secreted in a latent form due to noncovalent association with latency associated peptide (LAP), which is...

  • The End of the Line for Hookworm? An Update on Vaccine Development. Devaney, Eileen // PLoS Medicine;Oct2005, Vol. 2 Issue 10, p948 

    Deals with hookworm infection and vaccine development for the disease. Pathogenesis of hookworm infection; Treatment options; Proteases as potential vaccine candidates; Challenges facing efforts to develop hookworm vaccines.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics